Advances in neuroblastoma immunotherapy based on chimeric antigen receptor

  • ZHAO Jie ,
  • LI Benshang
Expand
  •  Department of Hematology and Oncology, Shanghai Children’s Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai 200127, China

Received date: 2018-05-15

  Online published: 2018-05-15

Abstract

Neuroblastoma is the most common extra-cranial malignant tumor in childhood. About 50% of the children have widespread metastatic diseases at initial diagnosis and the outcomes are poor. Chimeric antigen receptor (CAR) is a kind of genetically engineered receptors usually generated by extracellular antigen recognition region, spacer, transmembrane domain and intracellular endodomain. The antigen recognition region joining heavy and light chain variable regions of a monoclonal antibody with a linker to form a single-chain variable fragment (scFv) which can bind to tumor-associated antigens and lead to anti-tumor activity in an MHC-unrestricted manner. In this review, the recent advances and applications of CAR-T cell in neuroblostoma are reviewed and the application-related problems and possible solving strategies are discussed.

Cite this article

ZHAO Jie , LI Benshang . Advances in neuroblastoma immunotherapy based on chimeric antigen receptor[J]. Journal of Clinical Pediatrics, 2018 , 36(5) : 389 . DOI: 10.3969/j.issn.1000-3606.2018.05.017

Outlines

/